Treating CTCL by targeting the PI3K/AKT/mTOR pathway has been proven effective alone (64–67) or in combination with other strategies (45, 68), whereas the treatment responses vary among individuals. This evidence concerns the gene MTOR and primary cutaneous T-cell non-Hodgkin lymphoma.